Compare XLO & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | TELA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 37.5M |
| IPO Year | 2021 | 2019 |
| Metric | XLO | TELA |
|---|---|---|
| Price | $8.63 | $0.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $2.00 |
| AVG Volume (30 Days) | ★ 186.9K | 148.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | N/A | ★ N/A |
| Revenue | $43,766,000.00 | ★ $80,275,000.00 |
| Revenue This Year | $88.66 | $17.75 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | 15.84 |
| 52 Week Low | $0.46 | $0.54 |
| 52 Week High | $9.25 | $2.19 |
| Indicator | XLO | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 86.23 | 36.60 |
| Support Level | $0.63 | N/A |
| Resistance Level | $9.25 | $1.24 |
| Average True Range (ATR) | 0.60 | 0.12 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 70.82 | 19.25 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.